title: Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
authors.affiliation: Allon Therapeutics Inc, 506-1168 Hamilton Street, Vancouver, BC, Canada. bmorimoto@allontherapeutics.com
authors.forename: Bruce
authors.initials: B
authors.lastname: Morimoto
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D015507:Drugs, Investigational